Expanding the Scope of Targeted Radiopharmaceuticals
- Engineering 224Ra labelled microparticles (Radspherin®) to target cancer in body cavities
- Reducing off-target toxicities through targeting by proximity
- Presenting the latest clinical data and development plans for Radspherin® , currently in Phase 2 in ovarian cancer resulting from peritoneal carcinomatosis